Decibel Therapeautics

Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The firm focuses on hearing disorders, including noise-induced hearing loss, residual hearing preservation or improved sound fidelity with cochlear implants, presbycusis or age-related hearing loss, tinnitus, a persistent ringing in the ears, and genetic hearing loss. It also offers drugs for pediatric cancer and cystic fibrosis patients who experience ototoxicity or hearing loss. The company was founded by Kevin Paul Starr, M. Charles Liberman, Gabriel Corfas, Ulrich Müller, and Albert Edge in October 2015 and is headquartered in Boston, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Decibel Therapeutics is a developer of hearing disorder therapeutics intended to protect, repair and restore hearing. The company's therapeutics have provided insights into the link between hearing dysfunction and inner ear pathology and it has capabilities to encompass animal models, drug delivery to the inner ear, imaging, inner ear PK/PD modeling and measurement, bioinformatics, genetics and target identification, enabling patients to experience hearing loss therapies with different forms of hearing disorders for their recovery.

BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation and Rare Pediatric Disease Designation for the company's lead gene therapy product candidate, DB-OTO, for the treatment of patients with otoferlin-related congenital hearing loss.

Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the Company will participate in the following upcoming virtual investor conferences in September.

Decibel Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Cynthia Hu, J.D., as Chief Legal Officer and Corporate Secretary.

Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary

- Bolstered Board of Directors and Scientific Advisory Board with key appointments -

Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Decibel is a category leader in developing new medicines for hearing and balance disorders.

Decibel Therapeutics: Gene Therapies For Hearing Loss

Edgewise Therapeutics

Recursion Pharmaceuticals

Takeda Pharmaceutical

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Losers Outnumber Gainers in Biotech IPOs This Year

Adds leaders with expertise in hearing loss and balance disorders, combined with experience in gene therapy development Adds leaders with expertise in hearing loss and balance disorders, combined with experience in gene therapy development

Decibel Therapeutics Expands World-Class Scientific Advisory Board

BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the UBS Global Healthcare Virtual Conference on Wednesday, May 26, 2021 at 7:00 am ET.

Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference

– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO –

Decibel Therapeutics Reports First Quarter 2021 Financial Results and Corporate Update

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will present at the Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 pm ET.

Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds-

Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

Decibel Therapeutics Inc (NASDAQ: DBTX) presented preclinical data of its gene therapy candidate, DB-OTO, for hearing loss due to mutation of the otoferlin gene. Decibel presented the data at the Annual MidWinter Meeting of the Association for Research in Otolaryngology.

Decibel Therapeutics' Hearing Loss Gene Therapy Shows Potential In Preclinical Studies

Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference Podium presentations and posters shared at the 44th Annual Association for Research in Otolaryngology Conference

Decibel Therapeutics Presents Promising Preclinical Findings on DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin Mutations

Bumble

Fiserv

Anterix Inc

Corvus Pharmaceuticals

Molecular Templates

NexImmune

Oncorus

Prothena

Talis Biomedical

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

The Past Week's Notable Insider Buys: More Biotech IPOs, Bumble, Fiserv And More

BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), which will be held virtually February 20–24, 2021.

Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference

Adagene

Baosheng Media Group Holdings

Bioventus

Viant Technology

Longeveron

Cloopen Group Holding

Global Internet of People

Signify Health

Urban-gro

Vallon Pharmaceuticals

The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble, which completed the year's largest deal so far, and Chinese cloud services provider Cloopen Group, which bagged the biggest pop of 2021 to date.

U.S. IPO Weekly Recap: IPO Frenzy Brings The Year's Largest Deal And Biggest Pop In A 17 IPO Week

BOSTON, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the pricing of its initial public offering of 7,062,000 shares of its common stock at a price to the public of $18.00 per share. All of the shares of common stock are being offered by Decibel. In addition, Decibel has granted the underwriters a 30-day option to purchase up to an additional 1,059,300 shares of common stock at the public offering price, less underwriting discounts and commissions.

Decibel Therapeutics Announces Pricing of Initial Public Offering

News for Decibel Therapeautics Stock (DBTX)